Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate induced robust immune responses in nonhuman primates. H5N1 is a highly ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax Inc. closed 59.74% below its 52-week high of $17.81, which the company achieved on July 26th.

Novavax expects revenue of $4 billion to $5 billion this year in global sales, Trizzino said, noting "this is not just a pandemic question, it's an ongoing vaccination question." ...

Novavax COVID vaccine will still save lives, experts say, even with limited supply. There are still more than 26 million American adults who are unvaccinated.

The same can’t be said about the Novavax one. The Novavax Covid-19 vaccine includes a combination of the actual SARS-CoV-2 spike protein and what’s called the Matrix-M adjuvant.

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot ...